Target Name: RNF187
NCBI ID: G149603
Review Report on RNF187 Target / Biomarker Content of Review Report on RNF187 Target / Biomarker
RNF187
Other Name(s): RING domain AP1 coactivator 1 | Ring finger protein 187 | ring finger protein 187 | E3 ubiquitin-protein ligase RNF187 | ring domain AP-1 co-activator 1 | Protein RNF187 | RING finger protein 187 | RING-type E3 ubiquitin transferase RNF187 | RACO1 | RACO-1 | protein RNF187 | RN187_HUMAN

RNF187: A Potential Drug Target for Neurodegenerative Diseases

The RING domain AP1 coactivator 1 (RNF187) is a protein that plays a critical role in the regulation of gene expression and has been identified as a potential drug target in the field of neurodegenerative diseases.

RNF187 is a non-coding RNA molecule that is derived from the RNA-protein complex known as the RING-coactivator complex (RCC). The RCC is a protein-RNA interaction module that has been shown to play a role in the regulation of gene expression by affecting the stability and localization of RNA molecules.

One of the functions of the RCC is to enhance the stability of RNA molecules, such as microRNAs (miRNAs), by helping them to interact with specific protein partners, such as the RNA-protein complex. By doing so, the RCC increases the chances of these RNA molecules being translated into proteins and can influence the levels of protein expression in the cell.

In addition to its role in gene expression regulation, RNF187 has also been shown to play a role in the regulation of cellular processes such as cell growth, apoptosis, and autophagy.

The potential drug target for RNF187 is due to its involvement in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and can lead to a range of symptoms such as memory loss, confusion, and difficulty with daily tasks.

Recent studies have suggested that RNF187 may be a potential drug target for these conditions by virtue of its involvement in the regulation of neurodegenerative diseases. For example, studies have shown that RNF187 levels are decreased in the brains of individuals with Alzheimer's disease and that inhibiting its activity may increase the number of brain cells remaining in these individuals.

Another potential mechanism by which RNF187 may contribute to the development of neurodegenerative diseases is its role in the regulation of cellular processes that are implicated in the development of these conditions. For example, research has suggested that RNF187 may be involved in the regulation of axon growth and that this regulation may play a role in the development of neurodegenerative diseases.

In conclusion, RNF187 is a protein that has been identified as a potential drug target for neurodegenerative diseases. Its role in the regulation of gene expression and cellular processes makes it an attractive target for researchers and clinicians alike. Further studies are needed to fully understand the potential mechanisms of RNF187 as a drug target and to determine its effectiveness in the treatment of neurodegenerative diseases.

Protein Name: Ring Finger Protein 187

Functions: E3 ubiquitin-protein ligase that acts as a coactivator of JUN-mediated gene activation in response to growth factor signaling via the MAP3K1 pathway, independently from MAPK8

The "RNF187 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNF187 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RNF19A | RNF19B | RNF2 | RNF20 | RNF207 | RNF208 | RNF212 | RNF212B | RNF213 | RNF213-AS1 | RNF214 | RNF215 | RNF216 | RNF216-IT1 | RNF216P1 | RNF217 | RNF217-AS1 | RNF220 | RNF222 | RNF224 | RNF225 | RNF227 | RNF24 | RNF25 | RNF26 | RNF31 | RNF32 | RNF32-DT | RNF34 | RNF38 | RNF39 | RNF4 | RNF40 | RNF41 | RNF43 | RNF44 | RNF5 | RNF5P1 | RNF6 | RNF7 | RNF7P1 | RNF8 | RNFT1 | RNFT2 | RNGTT | RNH1 | RNLS | RNMT | RNPC3 | RNPC3-DT | RNPEP | RNPEPL1 | RNPS1 | RNPS1P1 | RNR1 | RNR2 | RNU1-1 | RNU1-100P | RNU1-108P | RNU1-11P | RNU1-134P | RNU1-18P | RNU1-3 | RNU1-31P | RNU1-32P | RNU1-36P | RNU1-38P | RNU1-4 | RNU1-42P | RNU1-55P | RNU1-61P | RNU1-63P | RNU1-72P | RNU1-73P | RNU1-78P | RNU1-7P | RNU1-82P | RNU1-88P | RNU105B | RNU11 | RNU12 | RNU2-1 | RNU2-17P | RNU2-2P | RNU2-4P | RNU2-54P | RNU2-5P | RNU2-6P | RNU4-1 | RNU4-14P | RNU4-2 | RNU4-30P | RNU4-33P | RNU4-38P | RNU4-39P | RNU4-46P | RNU4-53P | RNU4-62P | RNU4-6P | RNU4-76P